Diabetes Mellitus, Type 2

• Zurich, Oerlikon, Switzerland

Not specified

• Seoul, South Korea

• 1245.4.49003 Boehringer Ingelheim Investigational Site — Berlin, Germany
• 1245.4.49002 Boehringer Ingelheim Investigational Site — Mainz, Germany
• 1245.4.49001 Boehringer Ingelheim Investigational Site — Neuss, Germany

Not specified

• Investigational Site Number 10 — C.a.b.a., Argentina
• Investigational Site Number 14 — C.a.b.a., Argentina
• Investigational Site Number 01 — C.a.b.a., Argentina
• Investigational Site Number 11 — C.a.b.a., Argentina

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Singapore

• 1245.31.10145 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• 1245.31.10162 Boehringer Ingelheim Investigational Site — Glendale, Arizona, United States
• 1245.31.10124 Boehringer Ingelheim Investigational Site — Mesa, Arizona, United States
• 1245.31.10108 Boehringer Ingelheim Investigational Site — Phoenix, Arizona, United States

• Edegem, Belgium
• Hellerup, Denmark
• Vipperroed, Denmark
• Helsinki, Finland

• 1245.12.1 Boehringer Ingelheim Investigational Site — Kiel, Germany
• 1245.12.2 Boehringer Ingelheim Investigational Site — Neuss, Germany